We’re challenging the status quo so those who live with metastatic breast cancer have the potential to feel better, longer.
We know that from the moment of diagnosis, lives are forever changed. Much progress has been made within the breast cancer treatment space. But it is not enough.
At Olema, we are inspired by people and their stories and are determined to develop safer, more effective and convenient medicines to signal in a new day for those impacted by metastatic breast cancer.
View our clinical trials
Current clinical trials
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Please visit OPERA01study.com for more information about participation in the trial.
A Phase 1b Study in Combination With a CDK4/6 Inhibitor or With a PI3K Inhibitor
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients